Health Innovation

We are de-risking biomedical innovations, turning biomedical knowledge into social and economic value.

Health Innovation Assessment

Mercury Pharmaceuticals

Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.

If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.

By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

Women and men face different heart attack risks with diabetes

23

Oct 2026

Women and men face different heart attack risks with diabetes

Cholesterol abnormalities and high blood pressure contribute to diabetes-related heart attack risk, with significant implications for cardiovascular health.

What can 6,000 brain scans tell us about Alzheimer's?

23

Oct 2026

What can 6,000 brain scans tell us about Alzheimer's?

KARI's multimodal imaging dataset reveals critical insights into Alzheimer's disease, linking amyloid, tau, and brain structure to cognitive performance.

Babies born small may face lasting differences in school performance

23

Oct 2026

Babies born small may face lasting differences in school performance

The study highlights that fetal size, not just gestational age, plays a crucial role in long-term neurodevelopmental outcomes for term-born children.

Researchers harness cancer cells' carbon monoxide to produce anticancer drug

23

Oct 2026

Researchers harness cancer cells' carbon monoxide to produce anticancer drug

What if we could use a cancer's own byproduct to make drugs that destroy tumor cells from the inside? That is exactly what Katsunori Tanaka and his team have done at the RIKEN Pioneering Research Institute (PRI) in Japan.

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.

UNDERSTANDING INDUSTRIAL NEEDS

Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.

FOCUSED PROJECT MANAGEMENT

Smart approach to project management that helps speed up development stages and decision making.

INVESTMENT CAPABILITY

Availability of own investment up to 2m€ per project allows us to reach the next value milestone.